Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278-4286]

Affiliations

¹ Business and Decision Life Sciences for GSK, Wavre, Belgium. Electronic address: celine.x.marechal@gsk.com.
² GSK, King of Prussia, PA, USA.
³ Clinical Research Center, Tartu, Estonia.
⁴ Colchester Research Group, Truro, Nova Scotia, Canada.
⁵ GSK, Amsterdam, the Netherlands.
⁶ GSK, Wavre, Belgium.
⁷ Medicor Research Inc., Sudbury, Ontario, Canada.
⁸ Innomedica Medical Center, Tallinn, Estonia.

Free article

Published Erratum

Céline Maréchal et al. Vaccine. 2019.

Free article

. 2019 Feb 21;37(9):1252-1253.

doi: 10.1016/j.vaccine.2019.01.022. Epub 2019 Jan 30.

¹ Business and Decision Life Sciences for GSK, Wavre, Belgium. Electronic address: celine.x.marechal@gsk.com.
² GSK, King of Prussia, PA, USA.
³ Clinical Research Center, Tartu, Estonia.
⁴ Colchester Research Group, Truro, Nova Scotia, Canada.
⁵ GSK, Amsterdam, the Netherlands.
⁶ GSK, Wavre, Belgium.
⁷ Medicor Research Inc., Sudbury, Ontario, Canada.
⁸ Innomedica Medical Center, Tallinn, Estonia.

No abstract available

Erratum for

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.
Maréchal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC, Hervé C, Rheault P, Talli J, Wauters D, Oostvogels L. Maréchal C, et al. Vaccine. 2018 Jul 5;36(29):4278-4286. doi: 10.1016/j.vaccine.2018.05.110. Epub 2018 Jun 11. Vaccine. 2018. PMID: 29903674 Clinical Trial.